Ezra Cohen, MD of the University of California at San Diego discusses the potential role for PD-1 and PD-L1 monoclonal antibodies in Squamous Cell Head & Neck Carcinomas at ASTRO Head and Neck Symposium 2016.
Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses the trial results of Superoxide Dismotase Mimetic GC4419 to Reduce Chemoradiotherapy-induced Oral Mucositis at ASTRO Head and Neck Symposium 2016.
Ezra Cohen, MD of the University of California at San Diego discusses how the EGFR monoclonal antibody, Nimotuzumab, differ from cetuximab and panitumumab and If it's likely to play a therapeutic role in SCCHN at ASTRO Head and Neck Symposium 2016.
Dr. Jose Zevallos, MD of University of North Carolina Hospitals discusses his study which notes the type and number of HPV in Molecular Profile of HPV-positive Oropharyngeal Squamous Cell Carcinoma Stratified by Smoking Status at the ASTRO Head and Neck Symposium 2016
Jessica M. Frakes, MD of Moffitt Cancer Center states that HPV-positive oropharyngeal cancer can be found through imaging and physical exams within six months after treatment at ASTRO Head and Neck Symposium 2016.
Press Release: https://www.astro.org/uploadedFiles/Main_Site/News_and_Media/News_Releases/2016/HN16_Frakes.pdf
Dr. Bhishamjit S. Chera, MD of University of North Carolina Hospitals, Chapel Hill, North Carolina gives an overview of a Phase II Trial of De-intensified Chemoradiotherapy for Low-Risk HPV-associated Oropharyngeal Squamous Cell Carcinoma.
To perform a prospective, multi-institutional, phase 2 study of a substantial decrease in concurrent chemoradiation therapy (CRT) intensity as primary treatment for favorable-risk, human papillomavirusassociated oropharyngeal squamous cell carcinoma.
Methods and Materials
The major inclusion criteria were: (1) T0 to T3, N0 to N2c, M0; (2) human papillomavirus or p16 positive; and (3) minimal/remote smoking history. Treatment was limited to 60 Gy intensity modulated radiation therapy with concurrent weekly intravenous cisplatinum (30 mg/m2). The primary study endpoint was pathologic complete response (pCR) rate based on required biopsy of the primary site and dissection of pretreatment positive lymph node regions, regardless of radiographic response. Power computations were performed for the null hypothesis that the pCR rate is 87% and n=40, resulting in a type 1 error of 14.2%. Secondary endpoint measures included physician-reported toxicity (Common Toxicity Terminology for Adverse Events, CTCAE), patient-reported symptoms (PRO-CTCAE), and modified barium swallow studies.